JP2022551528A - カンナビノイドを含む経口医薬組成物およびその製造方法 - Google Patents
カンナビノイドを含む経口医薬組成物およびその製造方法 Download PDFInfo
- Publication number
- JP2022551528A JP2022551528A JP2022521638A JP2022521638A JP2022551528A JP 2022551528 A JP2022551528 A JP 2022551528A JP 2022521638 A JP2022521638 A JP 2022521638A JP 2022521638 A JP2022521638 A JP 2022521638A JP 2022551528 A JP2022551528 A JP 2022551528A
- Authority
- JP
- Japan
- Prior art keywords
- glutathione
- cannabinoids
- pharmaceutical composition
- oral pharmaceutical
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930003827 cannabinoid Natural products 0.000 title claims abstract description 90
- 239000003557 cannabinoid Substances 0.000 title claims abstract description 90
- 229940065144 cannabinoids Drugs 0.000 title claims abstract description 72
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 20
- 238000002360 preparation method Methods 0.000 title description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 154
- 108010024636 Glutathione Proteins 0.000 claims abstract description 77
- 229960003180 glutathione Drugs 0.000 claims abstract description 77
- 241000218236 Cannabis Species 0.000 claims abstract description 52
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000018417 cysteine Nutrition 0.000 claims abstract description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- 229960002433 cysteine Drugs 0.000 claims abstract description 6
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 claims abstract description 5
- BOTADXJBFXFSLA-WHFBIAKZSA-N (2s)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]-3-methylbutanoic acid Chemical compound OC(=O)[C@H](N)C(C)(C)SSC[C@H](N)C(O)=O BOTADXJBFXFSLA-WHFBIAKZSA-N 0.000 claims abstract description 5
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 claims abstract description 5
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 claims abstract description 5
- WHOHXJZQBJXAKL-DFWYDOINSA-N Mecysteine hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CS WHOHXJZQBJXAKL-DFWYDOINSA-N 0.000 claims abstract description 5
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 claims abstract description 5
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 claims abstract description 5
- 235000015295 alliin Nutrition 0.000 claims abstract description 5
- 229960004272 bucillamine Drugs 0.000 claims abstract description 5
- 229960004399 carbocisteine Drugs 0.000 claims abstract description 5
- IFERABFGYYJODC-LURJTMIESA-N felinine Chemical compound OCCC(C)(C)SC[C@H](N)C(O)=O IFERABFGYYJODC-LURJTMIESA-N 0.000 claims abstract description 5
- 229960001155 mecysteine hydrochloride Drugs 0.000 claims abstract description 5
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002798 polar solvent Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 16
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 14
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 14
- 229950011318 cannabidiol Drugs 0.000 claims description 14
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 4
- 229960004242 dronabinol Drugs 0.000 claims description 4
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003453 cannabinol Drugs 0.000 claims description 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
- 206010019851 Hepatotoxicity Diseases 0.000 abstract description 14
- 231100000304 hepatotoxicity Toxicity 0.000 abstract description 8
- 230000007686 hepatotoxicity Effects 0.000 abstract description 8
- 230000037406 food intake Effects 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 244000025254 Cannabis sativa Species 0.000 description 11
- 235000008697 Cannabis sativa Nutrition 0.000 description 9
- 231100000334 hepatotoxic Toxicity 0.000 description 8
- 230000003082 hepatotoxic effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000003405 ileum Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 241000224489 Amoeba Species 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009483 enzymatic pathway Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 241000224423 Acanthamoeba castellanii Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000499 nonhepatotoxic Toxicity 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
1つ以上のカンナビノイドからなる第1の医薬活性部分と、
グルタチオン、システイン、アセチルシステイン、アリイン、ブシラミン、カルボシステイン、ジェンコル酸、フェリニン、ランチオニン、メシステイン塩酸塩、ペニシラミンシステインジスルフィド、またはそれらの任意の機能的等価物のうちの1つ以上からなる第2の医薬活性部分と、
必要に応じて1つ以上の賦形剤と、
で構成され、
前記第2の医薬活性部分の前記第1の医薬活性部分に対するモル比が少なくとも0.5:1である経口医薬組成物を提供する。
i)溶媒を用いて、前記大麻植物材料から1つ以上のカンナビノイドを含有する第1の画分を抽出する工程と、
ii)同じ前記大麻植物材料からグルタチオンを含む第2の画分を抽出する工程と、
iii)前記第1の画分と前記第2の画分を乾燥させて組み合わせて、前記医薬組成物を形成する工程と、を含む方法を提供する。
大麻植物からカンナビノイドを溶媒抽出し、特定のカンナビノイドを分離することは、従来から公知である。米国特許第6,403,126号はそのような方法の1つを開示しており、当該特許に開示された方法は、本発明と共に使用するのに適している。特に、米国特許第6,403,126号の方法は、カンナビス・サティバからカンナビノイドを抽出する際に使用するのに適している。
・材料
乾燥したカンナビス・サティバの葉10g
脱イオン水100ml
250mlの三角フラスコ
磁気攪拌機および攪拌子
濾紙
フィルター漏斗
蒸発皿
乾燥オーブン
Claims (10)
- 1つ以上のカンナビノイドからなる第1の医薬活性部分と、
グルタチオン、システイン、アセチルシステイン、アリイン、ブシラミン、カルボシステイン、ジェンコル酸、フェリニン、ランチオニン、メシステイン塩酸塩、ペニシラミンシステインジスルフィド、またはそれらの任意の機能的等価物のうちの1つ以上からなる第2の医薬活性部分と、
必要に応じて1つ以上の賦形剤と、
で構成され、
前記第2の医薬活性部分の前記第1の医薬活性部分に対するモル比が少なくとも0.5:1である経口医薬組成物。 - 前記第2の医薬活性部分の前記第1の医薬活性部分に対するモル比が少なくとも0.8:1である請求項1に記載の経口医薬組成物。
- 前記第2の医薬活性部分の前記第1の医薬活性部分に対するモル比が少なくとも1:1である請求項1に記載の経口医薬組成物。
- 前記第1の医薬活性部分が、カンナビジオール、カンナビノール、テトラヒドロカンナビノール、またはそれらの混合物からなる請求項1に記載の経口医薬組成物。
- 前記第2の経口医薬組成物がグルタチオンからなる請求項1~4のいずれか一項に記載の経口医薬組成物。
- 大麻植物材料から請求項5に記載の経口医薬組成物を製造する方法であって、
i)極性溶媒を用いて、前記大麻植物材料から1つ以上のカンナビノイドを含有する第1の画分を抽出する工程と、
ii)水を用いて、同じ前記大麻植物材料からグルタチオンを含む第2の画分を抽出する工程と、
iii)前記第1の画分と前記第2の画分を乾燥させて組み合わせて、前記経口医薬組成物を形成する工程と、を含む、経口医薬組成物を製造する方法。 - 前記極性溶媒がエタノールである請求項6に記載の経口医薬組成物を製造する方法。
- 前記大麻植物材料が大麻植物細胞からなる請求項6または7に記載の経口医薬組成物を製造する方法。
- 前記大麻植物材料が乾燥した大麻植物からなる請求項6または7に記載の経口医薬組成物を製造する方法。
- 前記第1の画分および前記第2の画分を1つ以上の賦形剤と組み合わせて、前記経口医薬組成物を形成する請求項6~9のいずれか一項に記載の経口医薬組成物を製造する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1914719.8 | 2019-10-11 | ||
GB1914719.8A GB2588172B (en) | 2019-10-11 | 2019-10-11 | A pharmaceutical composition comprising cannabinoid |
PCT/EP2020/078263 WO2021069576A1 (en) | 2019-10-11 | 2020-10-08 | A pharmaceutical composition comprising cannabinoid |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022551528A true JP2022551528A (ja) | 2022-12-09 |
Family
ID=68619472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022521638A Pending JP2022551528A (ja) | 2019-10-11 | 2020-10-08 | カンナビノイドを含む経口医薬組成物およびその製造方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20210106636A1 (ja) |
EP (1) | EP4041217A1 (ja) |
JP (1) | JP2022551528A (ja) |
KR (1) | KR20220079918A (ja) |
CN (1) | CN114615997A (ja) |
CA (1) | CA3157691A1 (ja) |
GB (1) | GB2588172B (ja) |
IL (1) | IL292068A (ja) |
WO (1) | WO2021069576A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160325055A1 (en) * | 2015-05-08 | 2016-11-10 | Lunatech, Llc | Device To Deliver Cannabidiol And Associated Compounds To Promote Health |
WO2019104291A1 (en) * | 2017-11-27 | 2019-05-31 | La'au Pono | Combination of granulated dried botanical extract powder for symptom relief |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
WO2015068052A2 (en) * | 2013-10-31 | 2015-05-14 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
US20160331022A1 (en) * | 2015-05-12 | 2016-11-17 | Lunatech, Llc | Customized Vaporization Based On Environmental Or Personal Wellness Factors |
GB2551986A (en) * | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
-
2019
- 2019-10-11 GB GB1914719.8A patent/GB2588172B/en active Active
-
2020
- 2020-03-12 US US16/816,631 patent/US20210106636A1/en not_active Abandoned
- 2020-10-08 EP EP20800009.1A patent/EP4041217A1/en active Pending
- 2020-10-08 JP JP2022521638A patent/JP2022551528A/ja active Pending
- 2020-10-08 CN CN202080070514.8A patent/CN114615997A/zh active Pending
- 2020-10-08 CA CA3157691A patent/CA3157691A1/en active Pending
- 2020-10-08 KR KR1020227015281A patent/KR20220079918A/ko unknown
- 2020-10-08 WO PCT/EP2020/078263 patent/WO2021069576A1/en unknown
-
2022
- 2022-04-07 IL IL292068A patent/IL292068A/en unknown
- 2022-12-06 US US18/076,147 patent/US20230100385A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160325055A1 (en) * | 2015-05-08 | 2016-11-10 | Lunatech, Llc | Device To Deliver Cannabidiol And Associated Compounds To Promote Health |
WO2019104291A1 (en) * | 2017-11-27 | 2019-05-31 | La'au Pono | Combination of granulated dried botanical extract powder for symptom relief |
Non-Patent Citations (3)
Title |
---|
HSIN-YING WU; ET AL: "CANNABIDIOL HYDROXYQUINONE-INDUCED APOPTOSIS OF SPLENOCYTES IS MEDIATED 以下備考", TOXICOLOGY LETTERS, vol. VOL:195, NR:1, JPN5023001783, 19 May 2010 (2010-05-19), NL, pages 68 - 74, ISSN: 0005073379 * |
HSIN-YING WU; ET AL: "CANNABIDIOL INDUCED A CONTRASTING PRO-APOPTOTIC EFFECT BETWEEN FRESHLY ISOLATED 以下備考", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. VOL:246, NR:3, JPN5023001782, 21 May 2010 (2010-05-21), pages 141 - 147, ISSN: 0005073380 * |
MOLECULES, vol. 24, no. 2256, JPN6023021960, 17 June 2019 (2019-06-17), pages 1 - 12, ISSN: 0005073381 * |
Also Published As
Publication number | Publication date |
---|---|
GB2588172A (en) | 2021-04-21 |
KR20220079918A (ko) | 2022-06-14 |
EP4041217A1 (en) | 2022-08-17 |
CA3157691A1 (en) | 2021-04-15 |
GB201914719D0 (en) | 2019-11-27 |
CN114615997A (zh) | 2022-06-10 |
US20210106636A1 (en) | 2021-04-15 |
US20230100385A1 (en) | 2023-03-30 |
IL292068A (en) | 2022-06-01 |
GB2588172B (en) | 2023-05-24 |
WO2021069576A1 (en) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ferruzzi et al. | Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease | |
JP3245654B2 (ja) | コゴメバオトギリソウの安定な抽出物、その調製方法および薬学的組成物 | |
JP7490557B2 (ja) | ベルベリンを含む組成物 | |
US20140120181A1 (en) | Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent | |
Doğan et al. | Protective effect of silymarin and gallic acid against cisplatin-induced nephrotoxicity and hepatotoxicity | |
KR100509843B1 (ko) | 참당귀로부터 데커신 및 데커시놀 안젤레이트를 추출하는 방법 | |
JP4422685B2 (ja) | 肝保護のためのピニトールまたはカイロイノシトールの使用 | |
WO2007014379A2 (en) | A lipidic extract from lepidium meynii and its effect on the libido | |
JP2022551528A (ja) | カンナビノイドを含む経口医薬組成物およびその製造方法 | |
KR100414187B1 (ko) | 흰점박이꽃무지 추출물 및 이의 용도 | |
KR101144715B1 (ko) | 정자수 증가용 경구 투여제 | |
KR100337471B1 (ko) | 가공인삼추출물함유신장보호제조성물 | |
EP3954379A1 (en) | Compositions comprising phyllanthus extract for use in the treatment or prevention of a sars-cov-2 infection and/or at least one symptom of covid-19 | |
Kolure et al. | Protective effect of enicostemma axillare-swertiamarin on oxidative stress against nicotine-induced liver damage in sd rats | |
KR20100096566A (ko) | 간 질환 예방 또는 치료용 가공된 알로에 베라 추출물, 및 가공된 알로에 베라 추출물과 밀크씨슬의 배합요법 | |
CN111704622B (zh) | 黄烷醇-薄荷烷杂合体及其药物组合物与其制备方法和应用 | |
KR102628223B1 (ko) | 노르갈란타민을 포함하는 간 손상의 예방 또는 치료용 조성물 | |
RU2681649C1 (ru) | Композиция на основе празиквантеля для лечения описторхоза | |
JP2001335503A (ja) | ラジカル消去用医薬品 | |
JP2005532992A (ja) | 肝炎治療剤及び予防剤または肝臓保護剤として有用なソムオガルピ(AcanthopanaxKoreanum)抽出物 | |
Putri et al. | Effect of Boswellic Acid Administration on Blood Biochemical Profile of Sprague Dawley Rats in Cyclophosphamide-Induced Cardiotoxicity Conditions | |
Awad et al. | Effect of gingko biloba and onion juice on xanthine oxidase enzyme and renal function in induced hyperuricemic rats. | |
Mohamed | The Possibility of Using N-acetylcysteine as a Treatment for COVID-19 Patients | |
JPH0753385A (ja) | アルコール吸収抑制剤 | |
Ahmed et al. | Effect of Nigella Sativa on Biochemical Changes in Doxorubicin-induced Nephrotoxicity in Albino Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220607 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240308 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240513 |